Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study
Open Access
- 31 March 2019
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 186 (3) , e35-e39
Abstract
No abstract availableKeywords
Funding Information
- Janssen Research and Development
This publication has 5 references indexed in Scilit:
- Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaBlood, 2016
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007